Self-antigens represent the most relevant and abundant antigens to which the host's immune system must be tolerant. Induction and maintenance of tolerance to self-antigens is mediated by several mechanisms that prevent inappropriate damage to normal tissues. One mechanism that has gained significant attention in recent years relates to the critical role that bone marrow-derived antigen-presenting cells (APCs) play in the induction of tolerance to self-antigens. This emerging role of APCs in immune tolerance has been recently extended into the field of tumor immunology with the demonstration -as described in detail in this application- that tumor antigen processing and presentation by host's APCs also represents the dominant mechanism mediating tolerance to tumor antigens (""""""""cross-tolerance""""""""). The requirement for bone marrow derived APCs in both the induction of antigen-specific T-cell tolerance as well as in priming effective T-cell antitumor responses, places APCs at the center of a critical decision leading to immune activation versus immune tolerance. Although emerging evidence points to the state of activation and/or differentiation of the APC as the central determinant of T-cell priming versus tolerance, the signaling and molecular mechanism(s) involved in this critical decision remain to be elucidated. Therefore, in this proposal we will utilize a well-characterized model of tumor-induced antigen-specific T-cell tolerance to evaluate the role of Signal Transducer and Activator of Transcription-3 (Stat3), c-kit and mevalonate signaling pathways in the decision -at the APC level- leading to either tolerance or priming of antigen-specific T-cells. In addition, we will explore whether cross-tolerance to tumor antigens can be either prevented and/or reverted by strategies that target these intracellular signaling pathways in APCs. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100850-03
Application #
6858677
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Mccarthy, Susan A
Project Start
2003-04-15
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
3
Fiscal Year
2005
Total Cost
$290,140
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Sahakian, Eva; Powers, John J; Chen, Jie et al. (2015) Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol 63:579-85
Cheng, Fengdong; Lienlaf, Maritza; Perez-Villarroel, Patricio et al. (2014) Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 60:44-53
Cheng, Fengdong; Lienlaf, Maritza; Wang, Hong-Wei et al. (2014) A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol 193:2850-62
Woods, David M; Woan, Karrune; Cheng, Fengdong et al. (2013) The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res 23:341-8
Woan, Karrune V; Sahakian, Eva; Sotomayor, Eduardo M et al. (2012) Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 90:55-65
Wang, Hongwei; Cheng, Fengdong; Woan, Karrune et al. (2011) Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 186:3986-96
Brayer, Jason; Cheng, Fengdong; Wang, Hongwei et al. (2010) Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett 131:126-30
Vicente-Suarez, Ildelfonso; Brayer, Jason; Villagra, Alejandro et al. (2009) TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett 125:114-8
Villagra, Alejandro; Cheng, Fengdong; Wang, Hong-Wei et al. (2009) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10:92-100
Horna, Pedro; Sotomayor, Eduardo M (2007) Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets 7:41-53

Showing the most recent 10 out of 15 publications